VolitionRx Celebrates a Milestone Year with Key Advancements in Epigenetics and Diagnostics

A Transformational Year for VolitionRx



In 2026, VolitionRx Limited, a leading multi-national epigenetics company, reflected on a remarkable year characterized by significant clinical validations, strategic partnerships, and promising new directions in diagnostics. This progress has not only showcased the versatility of their Nu.Q® platform but has also set the stage for future advancements and market opportunities.

Noteworthy Achievements



Throughout the past year, VolitionRx achieved impressive milestones, including:
  • - Clinical Validation: Key data published in Critical Care Medicine confirmed that the Nu.Q® NETs H3.1 biomarker could predict 28-day mortality in septic patients, emphasizing its potential to drastically improve clinical outcomes in emergency care.
  • - Sepsis Screening Initiative: The launch of a €6.3 million government-funded program in France aims to evaluate the use of Nu.Q® NETs in emergency departments, potentially establishing it as a national screening standard for sepsis.
  • - Expansion of Technology: VolitionRx showcased its ability to develop a finger-prick test for sepsis, aligning with a letter of intent signed with Missionpharma for its global launch.

Advancements in Oncology



In the realm of oncology, VolitionRx made significant strides with its Capture-Seq™ technology, demonstrating efficacy in detecting early-stage cancers. In a blinded validation cohort comprising colorectal and lung cancer patients, Capture-Seq™ achieved:
  • - High Detection Rates: Over 94% of stage I and 96% of stage II cancers were detected, reinforcing the sensitivity and specificity of the technology.
  • - Peer-Reviewed Recognition: The first peer-reviewed paper on Capture-Seq™ was published in August, engaging the clinical community further in cancer detection innovation.
  • - Lung Cancer Reimbursement Efforts: Plans are underway for reimbursement submissions in France, highlighting the potential for wider adoption and implementation in clinical settings.

Expanding Animal Health Initiatives



Reflecting its commitment to advancing health across species, VolitionRx expanded its veterinary testing capabilities. Significant developments included:
  • - Feline Testing Advancements: The company revealed that its prototype could detect 86% of feline lymphomas, with an expectation for future milestone payments pending publication.
  • - Collaboration with Fujifilm: VolitionRx and Fujifilm Vet Systems expanded their partnership to launch Nu.Q® Vet tests specifically for cats in the Japanese market, further solidifying its place in veterinary diagnostics.

Financial Position and Outlook



On the financial side, 2026 has seen notable revenue growth. By September 30, revenues reached $3.0 million, reflecting a 134% increase compared to the previous year. The company also successfully reduced operating costs, achieving a 24% decrease in operating losses. This financial health positions VolitionRx favorably as it navigates through potential licensing agreements and partnerships impacting revenue streams.

The Road Ahead



Looking towards the future, VolitionRx is set to capitalize on its achievements in 2026. Key upcoming milestones include:
  • - The publication of its feline lymphoma manuscript, expected to unlock substantial milestone payments.
  • - Further licensing discussions with prominent diagnostic companies.
  • - Expansion of existing agreements and a push to finalize contracts with strategic partners, such as Sysmex and Werfen.
  • - Continual advancement of its initiatives in lung cancer detection and the DETECSEPS program for sepsis testing.

Cameron Reynolds, President and CEO of VolitionRx, stated, “This year has validated our commitment to pioneering advancements in diagnostic technology, which is crucial in tackling multi-billion-dollar markets. Our achievements not only signify scientific progress but also create pathways for future success.”

Conclusion



VolitionRx's forward-looking approach, combined with its groundbreaking research and strategic collaborations, positions it as a frontrunner in the epigenetics and diagnostics landscape. The company's unwavering dedication to enhancing patient outcomes and improving early detection methodologies exemplifies its pivotal role in the future of healthcare diagnostics.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.